




23 May 2023

## Life assurance



Source: Refinitiv

## Market data

EPIC/TKR	CSN
Price (p)	286.0
12m high (p)	334.4
12m low (p)	259.0
Shares (m)	150.4
Mkt cap (£m)	430.1
Economic Value (£m)	511.7
Country of listing	UK
Reporting currency	GBP
Market	London

## Description

Chesnara primarily manages and acquires closed life assurance books in the UK, Sweden and the Netherlands.

## Company information

CEO	Steve Murray
CFO	David Rimmington
Chairman	Luke Savage
	+44 (0)1772 972 050
	<a href="http://www.chesnara.co.uk">www.chesnara.co.uk</a>

## Key shareholders

abrdn	12.8%
Columbia Threadneedle	12.1%
M&G	6.4%
Interactive Investor	6.2%
Hargreaves Lansdowne	6.1%
Canaccord Genuity	5.7%
Janus Henderson	3.5%
Royal London	3.0%

## Diary

26 May	Final dividend paid
21 Sep	Interim results

## Analyst

Brian Moretta +44 (0)203 693 7075  
[bm@hardmanandco.com](mailto:bm@hardmanandco.com)

## CHESNARA PLC

## Nice little acquisition

Chesnara has announced its first acquisition of 2023. It is buying the onshore protection business from Canada Life's UK business. This consists of 47,000 term assurance and critical illness policies. Chesnara is paying £9m for the policies, and expects the Economic Value to be £16m – so this is a bit smaller than some of its more recent deals. The uplift of £7m increases Economic Value by ca.1.4%. Cash generation will be improved by ca.£16m over the next five years. This benefit is relatively front-end-loaded; so there will be a smaller cashflow benefit beyond the five years. This will have an almost neutral effect on the Solvency II ratio.


- ▶ **UK administration:** Chesnara has also announced a strategic partnership with SS&C Technologies for the administration of its UK operations. SS&C is an established provider of technology and administration services. Chesnara expects it to help with both ongoing administration and future M&A.
- ▶ **Estimates:** The Canada Life deal has led to small upgrades to our figures. We have increased our Economic Value earnings estimates by 1%. Cash generation sees a stronger effect, with our estimate increased by 8% for 2023 and 7% for 2024. Our 2023 and 2024 Economic Value per share estimates are also 3% higher.
- ▶ **Valuation:** With a price at under 80% of its forecast Economic Value, Chesnara seems undervalued. A prospective dividend yield of 8.4%, with good prospects of continued growth, also suggest an undervalued stock.
- ▶ **Risks:** Ultimately, the company remains tied to movements in financial markets and adverse developments in operational areas. Having just come through a testing period for the latter, in particular, we can see how well Chesnara can manage these challenges.
- ▶ **Investment summary:** Chesnara has three pillars for delivering value, under a responsible risk-based management. A close analysis reveals that there is substance underlying these aims. In our opinion, the discount to Economic Value looks wider than it should, and the yield appears high for a dividend that is both secure and growing.

## Financial summary and valuation

Year-end Dec (£m)	2019	2020	2021	2022	2023E	2024E
Operating earnings	5.6	-66.1	-58.8	-26.8	0.9	1.5
Economic earnings	121.1	22.9	109.6	-109.1	43.4	44.7
Economic Value earnings	104.0	-37.6	57.8	-106.1	45.2	47.1
Economic Value/share (p)	446	424	416	340	370	377
Base cash generation	37	28	20	83	55	52
EPS (p)	69.3	-25.1	38.5	-70.6	30.0	31.3
DPS (p)	21.30	21.94	22.60	23.28	23.98	24.70
Price/Economic Value (x)	0.64	0.67	0.69	0.84	0.77	0.76
Dividend yield	7.4%	7.7%	7.9%	8.1%	8.4%	8.6%


Source: Hardman &amp; Co Research

Economic Value earnings




- ▶ Volatility for investment assets in recent years and 2022
- ▶ Also affected by operational challenges
- ▶ Forecasts based on normalised assumptions
- ▶ Expected gains of £21m from Conservatrix and £7m from Canada Life in 2023

Base cash generation and dividends paid (line)




- ▶ 2020 affected by Scildon, and 2021 by a challenging Swedish market
- ▶ Symmetric adjustment smooths effect of markets on cash
- ▶ 2022 cash boosted by currency hedge
- ▶ Expected removal of headwinds should restore cash generation to comfortable levels

Economic Value



- ▶ Volatility for investment assets in recent years
- ▶ Also affected by operational challenges
- ▶ Forecasts based on normalised assumptions
- ▶ Gain from Sanlam and Robein Leven of £21m in 2022

Dividend per share



- ▶ Chesnara has been a consistent dividend payer for more than a decade and a half
- ▶ We forecast continued steady growth of 3% p.a.

Source: Company data, Hardman & Co Research

## Commentary

### Canada Life deal

It is almost a year since Chesnara's last new acquisition announcement. This clearly fits in with the company's strategy. In the UK, Canada Life has probably been more successful in its offshore business – so it shouldn't be a surprise that some of its onshore operations are small and seen as non-core.

This is a small acquisition for Chesnara. The policies are straightforward, and adding them to its systems should not preclude further acquisitions in the near term. Technically, the arrangement is through a reinsurance arrangement until the court can approve a Part VII transfer, which will probably take place in 2024. The latter is mostly procedural, but timing does depend on the UK court system. The net economic effect is that Chesnara will get the full benefit from 31 December 2022.

With an Economic Value of £16m and expected cash generation of ca.£16m in the first five years, it is clear that, from this perspective, the book is somewhat front-end-loaded. Although Canada Life only closed this line to new business in November 2022, this suggests that there have been few new policies in recent times.

Given the relatively small scale and short-term nature of the book, it would be a surprise if the effect on the Solvency II ratio were not the "broadly neutral" indicated in the announcement.

### SS&C Technologies partnership

Although this announcement will mean some significant changes in how the UK operations are run, the effect from an investor perspective is limited. Chesnara continues to endeavour to run its operations efficiently, and this requires periodic system reviews and updates.

From Chesnara's perspective, the main benefit seems to be greater flexibility when it comes to M&A. There should be some benefit to unit costs in the long run, but we are not making any allowance for that in our forecasts, and we implicitly expect Chesnara to bring down unit costs in due course.

### Forecasts

Recall that our forecasts are on a normalised basis. The structure of the Canada Life deal means that there will be benefits from FY'23. As indicated, we have made no adjustments for the SS&C partnership. We have assumed the following:

- ▶ Economic earnings will increase in line with the increase in Economic Value, i.e. +1%.
- ▶ We have added £16m to the Economic Value in 2023E, with a £7m gain.
- ▶ We have increased our cashflow estimates for the UK by £4m for 2023 and £3.6m for 2024. These are more significant than for the earnings, adding 8% to the 2023 estimated cashflow and 7% to 2024.

Economic Value earnings						
Year-end Dec (£m)	2019	2020	2021	2022	2023E	2024E
Expected movement	-0.4	0.3	-1.7	-1.3	0.0	0.0
New business	7.8	3.7	2.4	8.0	8.8	9.7
Operating experience variances	-6.8	-22.0	-19.2	-20.7	-7.9	-8.2
Operating assumption changes	3.8	-35.8	-13.9	-14.5	0.3	0.3
Other operating variances	-0.3	3.9	-0.2	1.7	-0.3	-0.3
Total u/l operating earnings	4.1	-49.9	-32.6	-26.8	0.9	1.5
Material other operating items	1.5	-16.2	-26.2	0.0	0.0	0.0
<b>Total operating earnings</b>	<b>5.6</b>	<b>-66.1</b>	<b>-58.8</b>	<b>-26.8</b>	<b>0.9</b>	<b>1.5</b>
Economic experience variances	143.1	45.7	79.5	0.0	41.1	42.3
Economic assumption changes	-22.0	-22.8	30.1	0.0	2.3	2.3
<b>Total economic earnings</b>	<b>121.1</b>	<b>22.9</b>	<b>109.6</b>	<b>-109.1</b>	<b>43.4</b>	<b>44.7</b>
Other non-operating variances	-5.2	-2.8	4.5	-2.6	3.6	3.7
Risk margin movement	-7.0	4.7	10.8	20.4	2.4	2.4
Tax	-10.5	3.7	-8.2	12.0	-5.0	-5.2
<b>Economic Value earnings</b>	<b>104.0</b>	<b>-37.6</b>	<b>57.8</b>	<b>-106.1</b>	<b>45.2</b>	<b>47.1</b>
Gain on acquisition	0.0	0.0	0.0	21.0	28.0	0.0
EPS (p)	69.3	-25.1	38.5	-70.6	30.0	31.3
DPS (p)	21.30	21.94	22.60	23.28	23.98	24.70

Source: Hardman & Co Research

While the normalised basis is our core expectation, in practice, results will rarely match the average. To give some idea of sensitivity, the following table gives estimates with two adjustments:

- ▶ annual equity returns of 3.5%, instead of 7%; and
- ▶ no returns from credit spreads, i.e. credit losses match the gain from the spread.

Investors can easily imply the effect of different assumptions from these. We note, however, that the first couple of months of the second half have been noticeably less volatile.

Sensitivity to economic assumptions				
£m	2021	2022E	2023E	2024E
Normalised Economic Value earnings	57.8	-106.1	45.2	47.1
Half equity returns			26.5	27.1
Reduction			-41%	-42%
No credit spreads			31.4	32.1
Reduction			-31%	-32%

Source: Hardman & Co Research

Given the market changes, our forecasts for group Economic Value have increased in line with the extra earnings and gain in 2024. Our 2023 and 2024 estimates for Economic Value per share have increased by 3%, to 370p and 377p per share, respectively.

The changes to the cashflow improve expected dividend cover for 2023 from 1.4x to 1.5x.

**Key balance sheet and cash generation**

Year-end Dec (£m)	2019	2020	2021	2022	2023E	2024E
Borrowings	88.2	67.0	47.2	212.0	212.0	212.0
Economic Value	670.0	636.8	624.2	511.7	556.5	567.2
Economic Value/share (p)	446	424	416	340	370	377
Base cash generation						
UK	33.6	29.5	27.4	40.8	33.7	30.3
Movestic	-6.2	12.4	-14.4	16.1	13.0	13.7
Waard	0.8	4.1	2.9	8.4	12.8	13.5
Scildon	22.6	-22.3	15.2	-3.4	5.4	5.6
Group	-14.0	4.1	-10.8	20.8	-10.2	-10.6
Total	36.8	27.8	20.3	82.7	54.7	52.4
Dividends paid	-31.3	-32.3	-33.3	-34.3	-35.4	-36.4
Dividend cash cover (x)	1.2	0.9	0.6	2.4	1.5	1.4

Source: Hardman & Co Research

## Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legals/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

## Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January 2018, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <https://ec.europa.eu/transparency/regdoc/rep/3/2016/EN/3-2016-2031-EN-F1-1.PDF>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.



[research@hardmanandco.com](mailto:research@hardmanandco.com)

1 Frederick's Place  
London  
EC2R 8AE  
[www.hardmanandco.com](http://www.hardmanandco.com)

+44 (0)20 3693 7075